

Programmi Uso Terapeutico Compassionevole	Promotore	Data Parere Unico CE	Documenti
Managed Access Program (MAP) to provide access to canakinumab treatment of cytokine release syndrome (CRS) in patients with COVID-19-induced pneumonia (CANAKINUMAB, ILARIS)	Novartis	07/04/2020	https://www.aifa.gov.it/documents/20142/1143282/Canakinumab_documenti.zip
Ruxolitinib Managed Access Program (MAP) for patients diagnosed with COVID19 and have severe/very severe lung disease (CINC424, RUXOLITINIB, JAKAVI)	Novartis	02/04/2020	https://www.aifa.gov.it/documents/20142/1140695/Ruxolitinib_documenti.zip
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection. (REMDESIVIR)	Gilead Sciences, Inc	26/03/2020	https://www.aifa.gov.it/documents/20142/1144520/Remdesivir_documenti.zip